The Australian Competition and Consumer Commission (ACCC) has launched legal action against pharmaceutical giant Reckitt Benckiser Australia for the marketing of its Nurofen Specific Pain Product range.
Products considered for this dispute include Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache.
The agency stated that making each product with the impression of addressing a particular type of pain is false or misleading, because the tables are in fact identical.
The drugs, frequently sold at different prices, contain the same active ingredient, specifically ibuprofen lysine 342mg.
ACCC is looking for “penalties and costs” from the UK-based pharmaceutical company, in addition to the “publication of corrective notices”.
ACCC Chairman Rod Sims said Nurofen products were listed on the Australian Register of Therapeutic Goods as able to treat a wide variety of pain types.
“In this case, we allege that consumers have been misled into purchasing Nurofen Specific Pain Products under the belief that each product is specifically designed for and effective in treating a particular type of pain, when this is not the case,” he said.
Reckitt Benckiser Australia however, said in a statement that it challenges any allegations that it had breached consumer law.
“All Nurofen packs are approved by the TGA and comply with TGA’s regulatory guidelines,” the retailer said. “Nurofen pain-specific products provide easier navigation of pain-relief options for a particular type of pain.”